Maggie Yuen Sells 2,432 Shares of Penumbra (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) CFO Maggie Yuen sold 2,432 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $342.30, for a total value of $832,473.60. Following the completion of the transaction, the chief financial officer owned 18,353 shares in the company, valued at approximately $6,282,231.90. The trade was a 11.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Penumbra Stock Performance

Shares of PEN stock traded down $0.59 on Wednesday, hitting $339.57. 721,659 shares of the stock were exchanged, compared to its average volume of 1,222,446. The firm’s 50 day moving average is $337.02 and its two-hundred day moving average is $293.94. Penumbra, Inc. has a one year low of $221.26 and a one year high of $362.41. The firm has a market capitalization of $13.33 billion, a PE ratio of 75.13, a P/E/G ratio of 2.10 and a beta of 0.81. The company has a current ratio of 6.64, a quick ratio of 4.29 and a debt-to-equity ratio of 0.01.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported $1.18 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.06. The company had revenue of $385.39 million for the quarter, compared to analysts’ expectations of $367.18 million. Penumbra had a net margin of 12.66% and a return on equity of 11.41%. Penumbra’s revenue was up 22.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.97 EPS. Sell-side analysts expect that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on PEN shares. BTIG Research downgraded Penumbra from a “buy” rating to a “neutral” rating and set a $349.00 target price for the company. in a research note on Thursday, January 15th. Leerink Partners lowered shares of Penumbra from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Bank of America boosted their price objective on shares of Penumbra from $320.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, January 5th. UBS Group reiterated a “neutral” rating and issued a $374.00 target price on shares of Penumbra in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat, Penumbra presently has a consensus rating of “Hold” and a consensus target price of $361.69.

Hedge Funds Weigh In On Penumbra

Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its position in Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after acquiring an additional 38 shares in the last quarter. Swiss Life Asset Management Ltd boosted its holdings in shares of Penumbra by 2.3% in the 4th quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after purchasing an additional 39 shares in the last quarter. Abbot Financial Management Inc. increased its position in shares of Penumbra by 1.3% during the 3rd quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company’s stock valued at $824,000 after purchasing an additional 42 shares during the last quarter. Glenview Trust Co raised its holdings in shares of Penumbra by 5.0% during the 3rd quarter. Glenview Trust Co now owns 904 shares of the company’s stock valued at $229,000 after buying an additional 43 shares in the last quarter. Finally, Keybank National Association OH lifted its position in Penumbra by 1.2% in the 4th quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock worth $1,152,000 after buying an additional 43 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.